Incannex Healthcare Inc. has executed a strategic warrant cancellation agreement that eliminates up to 347.2 million shares from potential future dilution, positioning the clinical-stage biopharmaceutical company ahead of critical Phase 2 trial results for its obstructive sleep apnea treatment expected in July 2025.
The company announced on May 28, 2025, that it entered into a binding agreement to cancel the remaining 172 million Series A Warrants for a payment of up to $12.2 million. Combined with an earlier tranche canceled on May 20, 2025, which removed 175.2 million dilution-linked shares, this transaction fully eliminates the overhang posed by Series A Warrants.
Strategic Capital Structure Optimization
"This is a significant milestone in strengthening our capital structure," said Joel Latham, President and CEO of Incannex. "Subject to final execution, this transaction ensures that up to 347 million shares will no longer be eligible to enter the market, providing clarity and confidence for our shareholders."
The timing of this financial restructuring coincides with Incannex's approach to releasing topline data from its Phase 2 RePOSA trial of IHL-42X for obstructive sleep apnea. The results are anticipated in July 2025, representing what Latham described as "one of the most important data readouts in the company's history."
IHL-42X: Targeting an Unmet Medical Need
IHL-42X is being developed as a potential first-in-class oral pharmaceutical treatment for obstructive sleep apnea, a condition affecting millions globally with no current FDA-approved drug therapy available. The investigational treatment is an oral fixed-dose combination of dronabinol and acetazolamide designed to target the underlying pathophysiology of OSA.
The drug candidate uniquely targets two physiological pathways associated with the intermittent hypoxia and hypercapnia that characterize OSA. In a prior Australian Phase 2 clinical trial, IHL-42X demonstrated efficacy across all dosage strengths, with the lowest dose reducing the Apnea-Hypopnea Index by an average of 51 percent relative to baseline.
Global Phase 2/3 Clinical Development
The ongoing RePOSA Phase 2/3 clinical trial is expected to enroll more than 560 patients at sites worldwide. The study is evaluating IHL-42X in individuals with OSA who are either non-compliant, intolerant, or naïve to positive airway pressure devices, including CPAP. The Phase 2 portion is being conducted in the United States.
"We've worked quickly and strategically to eliminate overhang and deliver a clean cap table, heading into one of the most important data readouts in the company's history," Latham added. "This transaction reflects our proactive approach to value creation and governance."
Broader Pipeline Development
Beyond its lead OSA program, Incannex is advancing additional combination therapies targeting chronic conditions with limited treatment options. The company's pipeline includes IHL-675A, an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate in Phase 2 development for inflammatory conditions such as rheumatoid arthritis, and PSX-001, an oral synthetic psilocybin treatment approved for Phase 2 clinical development for generalized anxiety disorder.
The warrant cancellation agreement represents a strategic financial maneuver designed to optimize Incannex's capital structure as it approaches a potentially pivotal clinical milestone that could establish IHL-42X as the first approved pharmaceutical treatment for obstructive sleep apnea.
